Serina Therapeutics (SER) EBT Margin (2018 - 2025)
Historic EBT Margin for Serina Therapeutics (SER) over the last 8 years, with Q2 2025 value amounting to 4287.69%.
- Serina Therapeutics' EBT Margin rose 38946600.0% to 4287.69% in Q2 2025 from the same period last year, while for Sep 2025 it was 20168.97%, marking a year-over-year decrease of 197906600.0%. This contributed to the annual value of 31382.14% for FY2024, which is 312652100.0% down from last year.
- Latest data reveals that Serina Therapeutics reported EBT Margin of 4287.69% as of Q2 2025, which was up 38946600.0% from 39757.14% recorded in Q4 2024.
- In the past 5 years, Serina Therapeutics' EBT Margin ranged from a high of 39757.14% in Q4 2024 and a low of 54140.0% during Q1 2022
- Moreover, its 5-year median value for EBT Margin was 8182.35% (2024), whereas its average is 14654.64%.
- As far as peak fluctuations go, Serina Therapeutics' EBT Margin tumbled by -505810700bps in 2022, and later soared by 506466700bps in 2023.
- Over the past 5 years, Serina Therapeutics' EBT Margin (Quarter) stood at 8377.78% in 2021, then tumbled by -312bps to 34500.0% in 2022, then skyrocketed by 100bps to 2.11% in 2023, then skyrocketed by 1888058bps to 39757.14% in 2024, then plummeted by -111bps to 4287.69% in 2025.
- Its last three reported values are 4287.69% in Q2 2025, 39757.14% for Q4 2024, and 38057.14% during Q3 2024.